Publications
CEBIO regularly contributes to publications on liquid biopsy, reference materials, and molecular diagnostics.
Please select from the list or browse our latest contributions.
file found.files found.
Simon K, Uhlig C, Jähne M, Uhlig S, Holdenrieder S, Bronkhorst A Market-Ready Cell Line-derived cfDNA Reference Materials for Liquid Biopsy Quality Assurance
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy.
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients – a CEPAC-TDM biomarker substudy.
Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.
Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie
Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.
Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19
Simon K, Uhlig C, Jähne M, Uhlig S, Holdenrieder S, Bronkhorst A Market-Ready Cell Line-derived cfDNA Reference Materials for Liquid Biopsy Quality Assurance
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy.
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients – a CEPAC-TDM biomarker substudy.
Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.
Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie
Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.
Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19
